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In Madin-Darby canine kidney D1 cells extracellular
nucleotides activate P2Y receptors that couple to several
signal transduction pathways, including stimulation of
multiple phospholipases and adenylyl cyclase. For one
class of P2Y receptors, P2Y2 receptors, this stimulation of
adenylyl cyclase and increase in cAMP occurs via the
conversion of phospholipase A2 (PLA2)-generated
arachidonic acid (AA) to prostaglandins (e.g. PGE2).
These prostaglandins then stimulate adenylyl cyclase
activity, presumably via activation of prostanoid recep-
tors. In the current study we show that agents that in-
crease cellular cAMP levels (including PGE2, forskolin,
and the b-adrenergic agonist isoproterenol) can inhibit
P2Y receptor-promoted AA release. The protein kinase A
(PKA) inhibitor H89 blocks this effect, suggesting that
this feedback inhibition occurs via activation of PKA.
Studies with PGE2 indicate that inhibition of AA release
is attributable to inhibition of mitogen-activated pro-
tein kinase activity and in turn of P2Y receptor stimu-
lated PLA2 activity. Although cAMP/PKA-mediated inhi-
bition occurs for P2Y receptor-promoted AA release, we
did not find such inhibition for epinephrine (a1-adrener-
gic) or bradykinin-mediated AA release. Taken together,
these results indicate that negative feedback regulation
via cAMP/PKA-mediated inhibition of mitogen-acti-
vated protein kinase occurs for some, but not all, classes
of receptors that promote PLA2 activation and AA re-
lease. We speculate that receptor-selective feedback in-
hibition occurs because PLA2 activation by different re-
ceptors in Madin-Darby canine kidney D1 cells involves
the utilization of different signaling components that
are differentially sensitive to increases in cAMP or, al-
ternatively, because of compartmentation of signaling
components.
Arachidonic acid (AA)1 and its eicosanoid metabolites (e.g.
prostaglandins and leukotrienes) play critical roles in the ini-
tiation or modulation of a broad spectrum of biological re-
sponses, including many inflammatory processes. In mamma-
lian cells AA is normally stored in membrane phospholipids
and released primarily by phospholipase A2 (PLA2). Among
several types of mammalian PLA2s, the 85-kDa cytosolic form
(cPLA2) appears to specifically catalyze receptor-promoted AA
release. Considerable efforts have been made in recent years to
study the mechanism for the activation of cPLA2 and the sub-
sequent release of AA. In a variety of cell types, cPLA2 activa-
tion occurs as a result of phosphorylation by mitogen-activated
protein (MAP) kinase (1).
We have recently demonstrated that in MDCK-D1 cells P2Y2
(previously termed P2U) purinergic receptor-promoted AA re-
lease is mediated through cPLA2 activation by MAP kinase (2).
Other data have shown that stimulation of P2Y2 purinergic
receptors in these cells also stimulates adenylyl cyclase (AC)
activity, increasing cellular cAMP levels through an autocrine/
paracrine mechanism involving prostaglandin E2 (PGE2) pro-
duction subsequent to cPLA2-mediated AA release (3, 4). In the
present study we sought to assess the relationship of these two
signaling pathways activated by P2Y2 purinergic receptors. We
found that activation of the AC system can inhibit cPLA2-
mediated AA release by P2Y2 purinergic receptors through the
inhibition of MAP kinase in MDCK-D1 cells. Therefore, we
define a negative feedback mechanism via an autocrine/para-
crine cycle in which P2Y2 receptors can attenuate the activation
of PLA2 and AA release initiated by receptor agonists.
EXPERIMENTAL PROCEDURES
Cell Culture—MDCK-D1 cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% serum and passaged every 3–4
days by trypsinization using trypsin/EDTA. Cells were used for exper-
iments when grown to approximately 70% confluence.
Assay of cAMP—Growth medium was removed from cells, and cells
were equilibrated for 30 min at 37 °C in serum-free Dulbecco’s modified
Eagle’s medium containing 20 mM Hepes buffer (DMEH, pH 7.4). Sub-
sequently cells were incubated in fresh DMEH with PGE2 for 5 min at
37 °C in the presence of 200 mM isobutylmethylxanthine or 100 mM
Ro20–1724, two different phosphodiesterase inhibitors. Reactions were
terminated by aspiration of medium and addition of 7.5% trichloroace-
tic acid. Intracellular cAMP levels were determined by radioimmuno-
assay (Calbiochem, CA) of trichloroacetic acid extracts following acety-
lation, as described previously (3).
[3H]AA Release in Intact Cells—Cells were labeled with [3H]AA by
incubation with 0.5 mCi of [3H]AA (specific activity, 100 Ci/mmol; NEN
Life Science Products) per ml for approximately 20 h in 24-well plates.
Cells were washed four times with DMEH supplemented with 5 mg/ml
bovine serum albumin and then incubated in the same medium at 37 °C
for 15–20 min to equilibrate the temperature. Agents of interest were
then added in 1 ml of 37 °C medium after removing equilibration
medium. Release of [3H]AA was assayed and normalized to the percent-
age of incorporated radioactivity, as described previously (2).
cPLA2 Activity Assay of Cell Lysates—cPLA2 activity was assayed in
lysates prepared from cells incubated with various agents, as described
previously (2). Briefly, cells were incubated with indicated agonists in
DMEH for 10 min at 37 °C, washed with ice-cold buffer containing 250
mM sucrose, 50 mM Hepes, pH 7.4, 1 mM EGTA, 1 mM EDTA, phospha-
tase inhibitors (200 mM Na3VO4, 1 mM levamisole) and protease inhib-
itors (500 mM phenylmethylsulfonyl fluoride, 8 mM pepstatin, 16 mM
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leupeptin, and 1 mM diisopropyl fluorophosphate), and then scraped
into ice-cold buffer identical to the washing buffer except that sucrose
was omitted but 100 nM okadaic acid and 1 mM dithiothrietol were
added. Scraped cells were sonicated, and cell lysates (supernatants
after centrifugation at 4 °C for 10 min at 500 3 g) were assayed for
cPLA2 using 1-stearoyl-2[
14C]arachidonyl-L-3-phosphatidyl choline as
substrate in the assay buffer described above containing 10 mg/ml
bovine serum albumin and 10 mM CaCl2. Cell lysates (100 ml) were
added to an equal volume of substrate in a shaking 37 °C water bath so
that final concentrations were, in addition to phosphatase and protease
inhibitors, 20 mM 1-stearoyl-2[14C]arachidonyl-L-3-phosphatidyl cho-
line, 5 mM CaCl2, 1 mM EGTA, 1 mM EDTA, 1 mM dithiothrietol, 50 mM
Hepes, pH 7.4, and 10–30 mg of protein (determined by a Bradford
protein assay kit (Bio-Rad) with a bovine serum albumin standard).
Reactions were stopped by adding 0.75 ml of 1:2 (v/v) chloroform/
methanol. Samples were processed and assayed for [14C]AA by thin
layer chromatography, as described previously (2).
Assay of Phospholipase D Activation—MDCK-D1 cells were labeled
by an overnight incubation with [3H] palmitate. Washed cells were then
incubated for 1 h with 20 mM indomethacin (to block PGE2 formation),
with 0.5 mM isobutylmethylxanthine for 20 min, with 20 mM PGE2 or
50 mM isoproterenol for 20 min, and then with either 300 mM ATP or
300 mM UTP for 10 min. Cells were lysed and phosphatidylethanol
was resolved by thin layer chromatography, as described previously (5).
Phosphatidylethanol was expressed as the percentage of total cellular
radioactivity.
Phosphorylation-induced Mobility Shift, SDS-Polyacrylamide Gel
Electrophoresis, and Immunoblotting of MAP Kinase—Cells were
washed five times with DMEH supplemented with 2 mg/ml bovine
serum albumin, incubated in this medium at 37 °C for 1 h, and then
with specified agonists for 3 min. Reactions were stopped by aspiration
of medium and washing of cells four times with ice-cold buffer (62.5 mM
Tris HCI, pH 6.8, plus 10% glycerol), and protease and phosphatase
inhibitors were used for PLA2 activity assays. Scraped cells were lysed
in SDS-polyacrylamide gel electrophoresis loading buffer and boiled for
five min, and samples were electrophoresed on SDS-polyacrylamide gel
electrophoresis using 7.5% acrylamide. Following transfer to an Immo-
bilon-P polyvinylidene fluoride membrane (Millipore) and blocking for
1 h with 5% nonfat dry milk dissolved in phosphate-buffered saline,
membranes were incubated with 1:2000–3000 diluted anti-p42 MAP
kinase rabbit serum for 90 min and then with 1:2000 diluted horserad-
ish-peroxidase-linked donkey anti-rabbit immunoglobulin for 1 h (both
in 5% nonfat dry milk dissolved in phosphate-buffered saline) and then
washed four times with phosphate-buffered saline (5 min each wash).
MAP kinase bands were visualized using ECL immunoblotting detec-
tion reagents (Amersham Pharmacia Biotech).
Data Presentation—Unless otherwise specified, the data shown in
figures are the means 6 S.D. of triplicate measurements and are
representative of results obtained in two to four experiments. Results
were analyzed for statistical significance by one-way analysis of vari-
ance (with Bonferroni’s correction, where appropriate).
RESULTS
Increase in Cellular cAMP Inhibits P2Y2 Receptor-promoted
AA Release and cPLA2 Activation in MDCK-D1 Cells—We have
previously demonstrated in MDCK-D1 cells that activation of
P2Y2 purinergic receptors results in AA release via activation of
cPLA2 (2) and that stimulation of P2Y2 purinergic receptors in
these cells can increase cellular cAMP levels via the action of
the PGE2 generated from AA (3, 4). To further investigate the
relationship of these two signaling pathways activated by P2Y2
receptors, we examined the effects of cAMP-increasing agents
on P2Y2 receptor-promoted AA release. As shown in Fig. 1,
agents that increase cAMP in MDCK- D1 cells (PGE2, forskolin,
and Ro20–1724) inhibited AA release stimulated by the P2
receptor agonists ATP and UTP. Isoproterenol also inhibited
the AA release stimulated by these purinergic agonists (data
not shown).
PGE2-mediated stimulation of cAMP and inhibition of P2Y2
receptor-promoted AA release displayed a similar concentra-
tion-response relationship, with a nearly maximal effect of
PGE2 achieved at 1–10 mM both for production of cAMP and
inhibition of AA release (Fig. 2). Because P2Y2 receptor-pro-
moted AA release in MDCK-D1 cells is mediated by activation
of cPLA2 (2), we tested whether an increase in cAMP would
blunt activation of this lipase. Indeed, as shown in Fig. 3,
activation of PLA2 activity in cell lysates by the specific P2Y2
agonist UTP was substantially inhibited by treatment of cells
with PGE2. Therefore, increases in cellular cAMP decrease AA
release and cPLA2 activation by P2Y2 receptors in MDCK-D1
cells.
MDCK-D1 cells possess a1-adrenergic receptors and B2-bra-
dykinin receptors that promote AA release in response to stim-
ulation by epinephrine and bradykinin, respectively (8–10). As
do P2Y2 receptors, a1-adrenergic receptors and bradykinin re-
ceptors promote AA release through activation of cPLA2 in
MDCK-D1 cells (2, 3, 7). Therefore, we tested whether increases
in cAMP would regulate AA release by these different recep-
tors. Unlike the results obtained for P2Y2 receptors, AA release
FIG. 1. Differential effects of PGE2 and forskolin on AA release
promoted by ATP, UTP, bradykinin, or epinephrine. MDCK-D1
cells labeled with [3H]AA were incubated with 10 mM PGE2 (A) or 30 mM
forskolin and/or 100 mM Ro20–1724 (B) for 20 min and then with either
medium (basal), 300 mM ATP (A only), 300 mM UTP, 50 mM epinephrine,
or 1 mM bradykinin for 10 min to measure [3H]AA release as described
under “Experimental Procedures.” *, p , 0.05.
FIG. 2. Concentration response of effects of PGE2 on cAMP
levels and 300 mM UTP-promoted AA release of MDCK-D1 cells.
Cells were assayed for [3H]AA or in parallel for cAMP content as
described under “Experimental Procedures” and in the legend to Fig. 1.
l, AA; E, cAMP.
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elicited by a1-adrenergic receptors and bradykinin receptors
was not inhibited by forskolin, Ro20–1724 (an inhibitor of
phosphodiesterase), or both (Fig. 1B). Treatment with PGE2
alone or with PGE2 and Ro20–1724 yielded similar results
(data not shown). Neither forskolin nor PGE2 stimulation of
cAMP accumulation was diminished by the presence of various
concentrations of epinephrine or bradykinin, as compared with
the presence of ATP or UTP (data not shown).
Activation of PKA and Inhibition of MAP Kinase Are Respon-
sible for the cAMP-mediated Inhibition of P2Y2 Receptor-pro-
moted AA Release—To test whether the inhibitory effect of the
increase in cellular cAMP on P2Y2 receptor-promoted AA re-
lease and cPLA2 activation in MDCK-D1 cells is mediated by
the activation of PKA, we examined the effect of the PKA
inhibitor H89 on PGE2-mediated inhibition of AA release. As
shown in Fig. 4, PGE2-mediated inhibition of ATP- or UTP-
stimulated AA release was completely prevented by pretreat-
ment of cells with H89, whereas H89 had no statistically sig-
nificant effect on basal or P2Y2 receptor-promoted AA release.
These data suggest that activation of PKA by cAMP is respon-
sible for the inhibitory effects of increased cellular cAMP levels
on P2Y2 receptor-promoted AA release.
Because MAP kinase plays a critical role in the activation of
cPLA2 and AA release in MDCK-D1 cells (2), we next assessed
whether activation of MAP kinase by P2Y2 receptors was inhib-
ited by pretreatment of cells with PGE2. Consistent with this
idea were results with epinephrine, which also activates MAP
kinase activity in MDCK-D1 cells (7). PGE2 blocked the MAP
kinase activation by UTP but not that by epinephrine (Fig. 5).
As shown in Fig. 6, the UTP-induced gel shift of MAP kinase
was inhibited by incubation of cells with PGE2. This PGE2-
mediated inhibition of MAP kinase was reversed by treatment
of cells with H89, suggesting that activation of PKA is respon-
sible for both the cAMP-mediated inhibition of MAP kinase
activation and inhibition of AA release and cPLA2 activation.
Based on these and previous data related to the role of MAP
kinase on P2Y receptor-promoted activation of cPLA2 in
MDCK-D1 cells, we conclude that the cAMP/PKA system neg-
atively regulates cPLA2 activated by P2Y2 receptors through
the inhibition of MAP kinase activation.
P2Y Receptor Activation of Phospholipase D Activity Is Not
Inhibited by Elevation of cAMP—In addition to activation
cPLA2, P2Y receptors can also increase phospholipase D activity
in MDCK-D1 cells (5). To determine whether the inhibitory
effect of cAMP on cPLA2 activation occurs at more upstream
levels of the signaling cascade, such as at the level of receptor
or G protein, we measured the effect of increasing cAMP on
phospholipase D activity. The inability of increases in cAMP to
FIG. 3. Effect of PGE2 on UTP-promoted activation of PLA2 in
MDCK-D1 cells. MDCK-D1 cells were incubated with or without 10 mM
PGE2 for 20 min and then with 300 mM UTP for 10 min. Cell lysates
were prepared, and PLA2 activity was assayed as described under
“Experimental Procedures.” The effect of PGE2 on UTP-promoted PLA2
activity was statistically significant. *, p , 0.05.
FIG. 4. Effect of H89 on PGE2-mediated inhibition of AA re-
lease promoted by ATP and UTP. [3H]AA-labeled MDCK-D1 cells
were incubated with either 10 mM PGE2 (20 min), 1.33 mM H89 (1 h prior
to PGE2 incubation), PGE2 plus H89, or with neither agent, and then
with 300 mM ATP or UTP for 10 min to measure [3H]AA release, as
described under “Experimental Procedures.” *, p , 0.05 relative to
control; #, p , 0.05 relative to PGE2 alone.
FIG. 5. Effect of PGE2 on activation of MAP kinase by UTP and
epinephrine. MDCK-D1 cells were incubated in the absence or pres-
ence of 10 mM PGE2 for 20 min and then with 50 mM epinephrine (Epi)
or 300 mM UTP for 3 min. MAP kinase activation was assessed as
described under “Experimental Procedures.”
FIG. 6. Effects of PGE2 and H89 on UTP-promoted activation of
MAP kinase. MDCK-D1 cells were incubated with 10 mM PGE2, 1.33
mM H89, or both as stated in the legend to Fig. 4 and then with or
without 300 mM UTP for 3 min. MAP kinase activation was assessed as
described under “Experimental Procedures.”
FIG. 7. Lack of effect of PGE2 and isoproterenol on ATP- and
UTP-promoted PLD activation. MDCK-D1 cells were labeled with
[3H]palmitate and then incubated with 20 mM PGE2 and 50 mM iso-
proterenol prior to incubation with 300 mM ATP or 300 mM UTP and
assayed for PLD activity, as described under “Experimental
Procedures.”
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blunt ATP- and UTP-mediated phospholipase D activity (Fig.
7) argues that a more distal, nonshared component, such as
MAP kinase (Figs. 5 and 6), is the site of negative regulation of
cPLA2/AA release by increases in cAMP.
DISCUSSION
Inhibitory effects of cAMP-increasing agents on AA release
have been observed in several previous studies (e.g. Refs. 11–
13). However, the molecular mechanism for this phenomenon
was not defined in these earlier studies. We recently showed
that P2Y2 receptors utilize MAP kinase and protein kinase Ca
as parallel pathways for the activation of cPLA2 in MDCK-D1
cells; blockade of either of these two pathways impairs the
activation of cPLA2 by P2Y2 receptor agonists (2). In the present
study, we found that activation of the AC/PKA system can
inhibit P2Y2 receptor-promoted cPLA2 activation by inhibiting
the MAP kinase signaling pathway. This finding is consistent
with the reports that cAMP and cAMP-mediated activation of
PKA can inhibit MAP kinase activation in other types of cells
(14–16).
AA release activated by P2Y2 receptors, but not activated
that by a1-adrenergic or B2-bradykinin receptors, was inhibited
by the AC/PKA system (Fig. 1). Because we have found that
MAP kinase appears not to be involved in the regulation of AA
release/cPLA2 activation by bradykinin receptors in MDCK-D1
cells (6), we were not surprised by the absence of inhibition of
bradykinin receptor-promoted AA release by the AC/PKA sys-
tem. Another group has used MDCK-D1 cells and observed
slight inhibition of bradykinin receptor-promoted AA release
by cAMP (17). However, a similar inhibition also was noted of
“basal” AA release in that study. The absence of inhibition by
the AC/PKA system on a1-adrenergic receptor-promoted AA
release was unexpected, because MAP kinase activation is re-
sponsible for AA release/cPLA2 activation by a1-adrenergic re-
ceptors in MDCK-D1 cells (7). The ability of the AC/PKA sys-
tem to inhibit P2Y2 receptor-mediated, but not a1-adrenergic
receptor-mediated activation of MAP kinase (Fig. 4), leads us to
conclude that the differential inhibitory effects of the AC/PKA
system on AA release lies in differences in MAP kinase activa-
tion by the two receptors. This conclusion is also supported by
studies showing a lack of inhibition by cAMP of P2 receptor-
mediated activation of PLD activity (Fig. 7). Other data indi-
cate that MAP kinase activation is not required for PLD acti-
vation by P2 receptors or a1-adrenergic receptors in MDCK
cells (18).2 We speculate that P2Y2 purinergic and a1b-adrener-
gic receptors are coupled to cPLA2 and MAP kinase through
different signaling pathways (perhaps via different G proteins)
that are differentially sensitive to increases in cAMP. Alterna-
tively, signaling components utilized by the two types of recep-
tors are compartmentalized such that increases in cAMP selec-
tively regulate components unique to the P2Y2 receptor pathway.
In conclusion, the present study demonstrates that the
AC/PKA system plays a negative role in the regulation of AA
release/cPLA2 activation by P2Y2 receptors through inhibition
of MAP kinase activation. This negative regulation occurs for
P2Y2 receptors but not for two other classes of receptors
coupled to cPLA2/AA release and is apparently secondary to
effects of cAMP/PKA to inhibit MAP kinase activation. Be-
cause the P2Y2 receptor can activate the AC/PKA system by
promoting cPLA2-mediated release of AA and its subsequent
conversion to PGE2 (3, 4), our results define a feedback cycle
whereby P2Y2 receptors in MDCK-D1 cells activate AA release
and production of PGE2. PGE2, in turn, activates the AC/PKA
system and then inhibits MAP kinase to decrease the AA
signaling cascade. Such a cycle could serve to produce homol-
ogous desensitization of the purinergic receptor pathway in
response to nucleotides and thus would blunt ongoing pro-
duction of AA and AA metabolites. Moreover, the cross-talk
that occurs between AC-stimulating pathways and the puri-
nergic pathway also represents a mechanism for the heterol-
ogous desensitization of the P2Y purinergic receptor pathway.
The feedback cycle described herein may contribute to both
physiologic and pharmacologic regulation of the P2Y puriner-
gic receptor signaling. Overall, these results, together with
evidence that P2Y2 receptors in MDCK-D1 cells are coupled to
cAMP production via release of AA and its conversion to
PGE2, define a potentially important feedback loop for regu-
lation of AA formation.
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